or Try an Advanced Search...

    Technical Analysis for YMAB - Y-mAbs Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 10.54 -2.95% -0.32
    YMAB closed down 2.95 percent on Wednesday, November 20, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical YMAB trend table...
    Date Alert Name Type % Chg
    180 Bearish Setup Bearish Swing Setup 0.00%
    Slingshot Bearish Bearish Swing Setup 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction -2.95%
    Lower Bollinger Band Walk Weakness -2.95%
    Wide Bands Range Expansion -2.95%
    Lower Bollinger Band Touch Weakness -2.95%
    Older End-of-Day Signals for YMAB ...

       Recent Intraday Alerts

    Alert Time
    Lower Bollinger Band Support about 19 hours ago
    Rose Above Previous Day's High about 22 hours ago
    Up 2% about 22 hours ago
    Up 1% about 22 hours ago
    Possible NR7 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    YMAB Chart by TradingView
    Basic chart:

    Profile

    Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Cancer Treatment Therapeutic Products Blastoma Brain Tumor Cancer Center Glioma Metastases Neuroblastoma Diffuse Intrinsic Pontine Glioma Kettering Cancer Center Memorial Sloan Refractory

    Is YMAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 9 Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
    Nov 8 Y-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call Transcript
    Nov 8 Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
    Nov 8 Y-mAbs Therapeutics GAAP EPS of -$0.16 beats by $0.01, revenue of $18.46M misses by $4.8M
    Nov 8 Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
    Nov 5 Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?
    Nov 4 Y-mAbs and Nobelpharma sign license and distribution agreement for DANYELZA in Japan
    Nov 4 Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
    Nov 1 Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
    Oct 25 Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
    See more YMAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 20.9
    52 Week Low 5.29
    Average Volume 239,007
    200-Day Moving Average 13.77
    50-Day Moving Average 13.82
    20-Day Moving Average 13.78
    10-Day Moving Average 12.71
    Average True Range 0.91
    RSI (14) 23.66
    ADX 36.32
    +DI 10.34
    -DI 41.74
    Chandelier Exit (Long, 3 ATRs) 13.38
    Chandelier Exit (Short, 3 ATRs) 13.07
    Upper Bollinger Bands 17.25
    Lower Bollinger Band 10.30
    Percent B (%b) 0.03
    BandWidth 50.49
    MACD Line -0.88
    MACD Signal Line -0.35
    MACD Histogram -0.5258
    Fundamentals Value
    Market Cap 459.77 Million
    Num Shares 43.6 Million
    EPS -0.45
    Price-to-Earnings (P/E) Ratio -23.42
    Price-to-Sales 6.16
    Price-to-Book 5.71
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.68
    Resistance 3 (R3) 11.74 11.43 11.49
    Resistance 2 (R2) 11.43 11.14 11.40 11.43
    Resistance 1 (R1) 10.98 10.96 10.83 10.92 11.36
    Pivot Point 10.67 10.67 10.59 10.64 10.67
    Support 1 (S1) 10.22 10.38 10.07 10.16 9.72
    Support 2 (S2) 9.91 10.20 9.88 9.65
    Support 3 (S3) 9.46 9.91 9.59
    Support 4 (S4) 9.40